Cancer therapy and treatments during COVID-19 era Review
| Authors: | Akula, S. M.; Abrams, S. L.; Steelman, L. S.; Candido, S.; Libra, M.; Lerpiriyapong, K.; Cocco, L.; Ramazzotti, G.; Ratti, S.; Follo, M. Y.; Martelli, A. M.; Blalock, W. L.; Piazzi, M.; Montalto, G.; Cervello, M.; Notarbartolo, M.; Basecke, J.; McCubrey, J. A. |
| Review Title: | Cancer therapy and treatments during COVID-19 era |
| Abstract: | The COVID-19 pandemic has put a serious strain on health treatments as well at the economies of many nations. Unfortunately, there is not currently available vaccine for SARS-Cov-2/COVID-19. Various types of patients have delayed treatment or even routine check-ups and we are adapting to a virtual world. In many cases, surgeries are delayed unless they are essential. This is also true with regards to cancer treatments and screening. Interestingly, some existing drugs and nutraceuticals have been screened for their effects on COVID-19. Certain FDA approved drugs, vitamin, natural products and trace minerals may be repurposed to treat or improve the prevention of COVID-19 infections and disease progression. This review article will summarize how the treatments of various cancer patients has changed during the COVID-19 era as well as discuss the promise of some existing drugs and other agents to be repurposed to treat this disease. © 2020 Elsevier Ltd |
| Keywords: | natural products; cancer; nutraceuticals; covid-19; repurposing approved drugs |
| Journal Title: | Advances in Biological Regulation |
| Volume: | 77 |
| ISSN: | 2212-4926 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2020-08-01 |
| Start Page: | 100739 |
| Language: | English |
| DOI: | 10.1016/j.jbior.2020.100739 |
| PROVIDER: | scopus |
| PMCID: | PMC7319627 |
| PUBMED: | 32773105 |
| DOI/URL: | |
| Notes: | Kvin Lertpiriyapong's last name is misspelled on the original publication -- Review -- Export Date: 3 August 2020 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work